BR112018072988A2 - irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula - Google Patents
irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célulaInfo
- Publication number
- BR112018072988A2 BR112018072988A2 BR112018072988-4A BR112018072988A BR112018072988A2 BR 112018072988 A2 BR112018072988 A2 BR 112018072988A2 BR 112018072988 A BR112018072988 A BR 112018072988A BR 112018072988 A2 BR112018072988 A2 BR 112018072988A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- lung cancer
- small cell
- cell lung
- administration
- Prior art date
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 title abstract 3
- 229960004768 irinotecan Drugs 0.000 title abstract 3
- 206010041067 Small cell lung cancer Diseases 0.000 title abstract 2
- 208000000587 small cell lung carcinoma Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000003637 steroidlike Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337961P | 2016-05-18 | 2016-05-18 | |
| US62/337,961 | 2016-05-18 | ||
| US201662345178P | 2016-06-03 | 2016-06-03 | |
| US62/345,178 | 2016-06-03 | ||
| US201662362735P | 2016-07-15 | 2016-07-15 | |
| US62/362,735 | 2016-07-15 | ||
| US201662370449P | 2016-08-03 | 2016-08-03 | |
| US62/370,449 | 2016-08-03 | ||
| US201662394870P | 2016-09-15 | 2016-09-15 | |
| US62/394,870 | 2016-09-15 | ||
| US201662414050P | 2016-10-28 | 2016-10-28 | |
| US62/414,050 | 2016-10-28 | ||
| US201662415821P | 2016-11-01 | 2016-11-01 | |
| US62/415,821 | 2016-11-01 | ||
| US201662422807P | 2016-11-16 | 2016-11-16 | |
| US62/422,807 | 2016-11-16 | ||
| US201662433925P | 2016-12-14 | 2016-12-14 | |
| US62/433,925 | 2016-12-14 | ||
| US201762455823P | 2017-02-07 | 2017-02-07 | |
| US62/455,823 | 2017-02-07 | ||
| US201762474661P | 2017-03-22 | 2017-03-22 | |
| US62/474,661 | 2017-03-22 | ||
| PCT/IB2017/000681 WO2017199093A1 (en) | 2016-05-18 | 2017-05-17 | Nanoliposomal irinotecan for use in treating small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018072988A2 true BR112018072988A2 (pt) | 2019-04-09 |
Family
ID=59258274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018072988-4A BR112018072988A2 (pt) | 2016-05-18 | 2017-05-17 | irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230000858A1 (enExample) |
| EP (1) | EP3458059A1 (enExample) |
| JP (3) | JP2019516693A (enExample) |
| KR (1) | KR20190009319A (enExample) |
| CN (1) | CN109640995A (enExample) |
| AU (1) | AU2017267449A1 (enExample) |
| BR (1) | BR112018072988A2 (enExample) |
| CA (1) | CA3023743A1 (enExample) |
| IL (1) | IL262656A (enExample) |
| MA (1) | MA45046A (enExample) |
| MX (1) | MX394766B (enExample) |
| PH (1) | PH12018502422A1 (enExample) |
| SG (2) | SG11201809788VA (enExample) |
| TW (1) | TWI791437B (enExample) |
| UA (1) | UA125646C2 (enExample) |
| WO (1) | WO2017199093A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| BR112018002941B1 (pt) | 2015-08-21 | 2023-12-05 | Ipsen Biopharm Ltd | Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas |
| BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2424792C2 (ru) * | 2004-05-03 | 2011-07-27 | Хермес Байесайенсиз, Инк. | Липосомы, используемые для доставки лекарственных средств |
| ES2550759T3 (es) * | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2017
- 2017-05-17 MA MA045046A patent/MA45046A/fr unknown
- 2017-05-17 CN CN201780042803.5A patent/CN109640995A/zh active Pending
- 2017-05-17 EP EP17734449.6A patent/EP3458059A1/en not_active Withdrawn
- 2017-05-17 MX MX2018013873A patent/MX394766B/es unknown
- 2017-05-17 JP JP2018559186A patent/JP2019516693A/ja not_active Withdrawn
- 2017-05-17 CA CA3023743A patent/CA3023743A1/en active Pending
- 2017-05-17 AU AU2017267449A patent/AU2017267449A1/en not_active Abandoned
- 2017-05-17 SG SG11201809788VA patent/SG11201809788VA/en unknown
- 2017-05-17 KR KR1020187035369A patent/KR20190009319A/ko not_active Ceased
- 2017-05-17 BR BR112018072988-4A patent/BR112018072988A2/pt not_active Application Discontinuation
- 2017-05-17 UA UAA201812255A patent/UA125646C2/uk unknown
- 2017-05-17 SG SG10201912407YA patent/SG10201912407YA/en unknown
- 2017-05-17 WO PCT/IB2017/000681 patent/WO2017199093A1/en not_active Ceased
- 2017-05-18 TW TW106116523A patent/TWI791437B/zh active
-
2018
- 2018-10-28 IL IL262656A patent/IL262656A/en unknown
- 2018-11-16 PH PH12018502422A patent/PH12018502422A1/en unknown
-
2020
- 2020-05-14 JP JP2020085131A patent/JP2020117548A/ja not_active Withdrawn
-
2021
- 2021-11-15 JP JP2021185609A patent/JP2022010295A/ja active Pending
-
2022
- 2022-03-21 US US17/699,374 patent/US20230000858A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516693A (ja) | 2019-06-20 |
| CN109640995A (zh) | 2019-04-16 |
| IL262656A (en) | 2018-12-31 |
| SG11201809788VA (en) | 2018-12-28 |
| UA125646C2 (uk) | 2022-05-11 |
| MX394766B (es) | 2025-03-24 |
| EP3458059A1 (en) | 2019-03-27 |
| JP2022010295A (ja) | 2022-01-14 |
| TW201740946A (zh) | 2017-12-01 |
| SG10201912407YA (en) | 2020-02-27 |
| JP2020117548A (ja) | 2020-08-06 |
| CA3023743A1 (en) | 2017-11-23 |
| TWI791437B (zh) | 2023-02-11 |
| MX2018013873A (es) | 2019-02-14 |
| US20230000858A1 (en) | 2023-01-05 |
| WO2017199093A1 (en) | 2017-11-23 |
| AU2017267449A1 (en) | 2018-11-15 |
| KR20190009319A (ko) | 2019-01-28 |
| MA45046A (fr) | 2019-03-27 |
| PH12018502422A1 (en) | 2019-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018072988A2 (pt) | irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula | |
| MX392408B (es) | Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina). | |
| BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
| BR112014031088A2 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
| CL2017001364A1 (es) | Nuevos indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos. | |
| BR112015026095A2 (pt) | métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral | |
| MX381475B (es) | Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer. | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| BR112018013245A2 (pt) | método e aparelho para administração óxido nítrico com drogas suplementares | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| BR112018006817A2 (pt) | método de tratamento do câncer | |
| MX385425B (es) | Irinotecán liposomal y oxaliplatino, 5-fluoroacilo y leucovorina para usarse en el tratamiento de cáncer pancreático metastásico. | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| ECSP14010868A (es) | Fenilimidazopirazoles sustituidos y su uso | |
| BR112015032728A2 (pt) | formulação compósita em cápsula farmacêutica compreendendo tadalafil e tansulosina | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| BR112017025553A2 (pt) | composição de vacina, e kit | |
| UY36408A (es) | Derivados de pirido benzodiazepina sustituidos y su utilización |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2646 DE 21/09/2021 POR TER SIDO INDEVIDA. |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |